Sedivention, a Medtech startup, has secured €800,000 in Pre-Seed funding from HTGF to develop a groundbreaking minimally invasive therapy for obesity.

Information on the Target

Sedivention GmbH, founded in 2021 near Munich, is a Medtech startup that specializes in developing innovative therapeutic devices for obesity. The company's primary product is a cryo-catheter designed to provide a one-time, minimally invasive intervention that targets the vagus nerve to aid in weight management. This device aims to address a critical health issue, as obesity is increasingly recognized as a complex medical condition rather than a simple matter of lifestyle choices.

Sedivention has already successfully developed and tested a prototype of its product, demonstrating both safety and efficacy. With a skilled team of experienced engineers and medical professionals, the startup is now poised to advance its product development and commence its first clinical trials.

Industry Overview in Germany

The obesity epidemic is a growing concern in Germany, mirroring global trends. Currently, obesity is responsible for approximately 3.7 million deaths per year worldwide, and this figure is projected to rise dramatically. By 2030, it is es